/PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...
/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting...
/PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid", or the "Company"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and...
/PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing...
/PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing...
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
/PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of...
BERKELEY HEIGHTS, N.J., Sept. 13, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC), (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabin
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (the "Company" or "Actinium") today announced that it has successfully completed the first...
/PRNewswire/ -- AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T...
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the University of Louisville and the...
/PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address...
/PRNewswire/ -- Ryvu Therapeutics (WSE:RVU) today announced the online publication of two posters and an oral presentation demonstrating clinical and...
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted new data from a Phase 1 trial studying Actimab-A in...
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will host a CD33 program update featuring two key...
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that first-in-human data from the first dose...
/PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell...
/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...
/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that...
/PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing...
/PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases,...
/PRNewswire/ -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
/PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its...
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU) today announced that abstracts regarding Phase 1/2 study of its selective CDK8 inhibitor SEL120 and dual PIM/FLT3...
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that interim data from its ongoing Actimab-A...
KRAKOW, Poland, Nove. 6, 2019 Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address...
❮
❯
Owing to the heterogeneity of AML, the indication for allogeneic SCT (allo-SCT) requires an exact definition of the individual subentity and risk category. A comprehensive diagnostic approach is needed, which combines cytomorphology, cytogenetics, FISH, molecular genetics and immunophenotyping. Whereas the categorization in three prognostic karyotype groups is well established, rare recurrent aberrations as the unfavorable t(8;16)(p11;p13), inv(3)(q21q26) and t(6;9)(p23;q34) must also be conside
Prognosis of acute myeloid leukemia (AML) depends on various factors. The fast-growing nature of this cancer requires timely management of the disease to increase survival rates.
A large-scale analysis of patients whose myelodysplastic syndrome is related to earlier cancer treatment overturns the notion that all of them have a poor prognosis.
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial i
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.
Fundamental processes such as ribosomal RNA synthesis and chromatin remodeling take place in the nucleolus, which is hyperactive in fast-proliferating cells. The sophisticated regulatory mechanism underlying the dynamic nucleolar structure and functions is yet to be fully explored. The present study uncovers the mutual functional dependency between a previously uncharacterized human long non-coding RNA, which we renamed LETN, and a key nucleolar protein, NPM1. Specifically, being upregulated in
Correspondence
Article
Researchers have described how the most common gene mutation found in acute myeloid leukemia starts the process of cancer development and how it can cooperate with other mutations to cause full-blown leukemia. The researchers suggest that three critical steps can transform normal blood cells into leukemic ones. By charting the route towards cancer, the study identifies processes that might could be targets for new treatments for patients with acute myeloid leukemia.
Trovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute Myelogenous Leukemia
An international group of researchers, including those from Moffitt Cancer Center in Tampa, Fla., have published a paper in the March 14 issue of the New England Journal of Medicine reviewing the results of a study that analyzed mutations in 18 genes of 398 patients who had acute myeloid leukemia (AML).
An international consortium of researchers from Seattle, London and Australia report the first use of a sensitive molecular test to measure the precise extent of remission or the likelihood of relapse in cancer patients being treated on Gleevec or a combination therapy consisting of interferon and cytarabine. The test is hundreds of thousands of times more sensitive than any other test making it a way to detect relapse earlier than ever before.
Review Article
Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia
EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2024
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.
Translocations involving the mixed lineage leukemia (MLL) gene, localized at 11q23, frequently occur in pediatric acute myeloid leukemia (AML). We recently reported differences in prognosis between the different translocation partners, suggesting differences in biological background. To unravel the latter, we used microarrays to generate gene expression profiles of 245 pediatric AML cases, including 53 MLL-rearranged cases. Thereby, we identified a specific gene expression signature for t(9;11)(
Original Article
Patients with acute myeloid leukemia (AML) could be separated genomically into at least 11 major groups, each with different constellations of genetic changes and distinctive clinical features. This genetic complexity helps explain why AML shows such variability in survival rates among patients. Full knowledge of the genetic make-up of a patient's leukemia substantially improved the ability to predict whether that patient would be cured with current treatments.
Leukemia and myeloproliferative disorders are serious and often deadly blood cancers.
Blood Cancer Journal is a peer-reviewed, open access online journal publishing pre-clinical and clinical work in the field of hematology with ramifications into translational biology research down to new therapies
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.
Article
Results of the EORTC and GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto) AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia. In particular, high-dose cytarabine produces higher remission and survival rates than the standard-dose cytarabine in patients younger than age 46 years old.
Blood Cancer Journal is a peer-reviewed, open access online journal publishing pre-clinical and clinical work in the field of hematology with ramifications into translational biology research down to new therapies
Nucleophosmin (NPM), also known as nucleolar phosphoprotein B23 or numatrin, is a protein that in humans is encoded by the NPM1 gene.
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.
❮
❯
/PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and...
Sunshine Heart will test device that runs on power transmitted through the skin.
Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease
/PRNewswire/ -- Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders,...
/PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Addison's Disease (Primary or Chronic Adrenal...
The company will launch a phase 3 study of its lead drug candidate this quarter.
OnCourse Learning Partners With Compliance Education Institute to Offer New Portfolio of Vendor
/PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months delay for the planned Phase Ib study...
Nordic Nanovector ASA - Results for Second Quarter and First Half Year 2017
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance...
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio,...
27.01.2020 - Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who ha
ROCKVILLE, Md., June 29, 2015 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect...
Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
Infantrymen have a love/hate relationship with artillery They love it, because if they have a lot of big guns supporting them, they can blast the enemy and then advance against a lot less resistance But being on the other end of that situation is decid
/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
Apellis Pharmaceuticals has a strong track record of developing innovative therapies for patients with unmet medical needs. Find out why APLS stock is a speculative buy.
Angionetics & A Huapont Life Sciences Affiliate Enter Agreement To Commercialize Generx®
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new data from its schizophrenia portfolio as part of the virtual 2020 Congress...
Northrop Grumman Corp <NOC.N> has hired two investment banks to sell a unit that advises government military agencies in a deal that could fetch up to $2 billion, a source familiar with the matter told Reuters.
/PRNewswire/ -- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting...
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by...
A key FDA panel is to vote on whether to recommend J&J's Covid vaccine for emergency use, which would help pave the way for a third vaccine in the U.S.
Phase 3b Study Shows Significantly Less Bleeding with XARELTO® (rivaroxaban) Compared to Warfarin
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s
❮
❯
AI Therapeutics has made significant recent progress with its four clinical assets and proprietary Guardian Angel™ algorithm.
/PRNewswire/ -- BIAL - R&D Investments S.A (BIAL R&D), a subsidiary of BIAL Holding, S.A., today announced the dosing of the first patient in its Phase 2...
/PRNewswire/ -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
PMV Pharma Secures $74 Million in Series B Financing for Cancer Drugs Targeting p53
EntreMed Receives Notice of NASDAQ Compliance
/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801,...
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative...
Article contends that leaving aside science fiction scenarios and ethical debates, first products to emerge from remarkable cloning of an adult sheep by British researchers will probably be animals that can serve as drug factories (M)
AMSTERDAM, May 20, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced...
/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying...
ClinTex CTi Leverages Distributed Ledger Technology to Lower the Cost of New Medicine and Improve Patients’ Lives.
Envisia Therapeutics Selected To Present During Anterior Segment Company Showcase At 2016
AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory
Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer
/PRNewswire/ -- Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced the completion of enrollment for its global Phase 2b...
/PRNewswire/ -- Oncorena, dedicated to developing a unique and potential breakthrough therapy for metastatic renal cancer, today announces the Swedish Medical...
/PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases,...
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc., (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and nine months ended September 30, 2010, and presented an update on recent clinical and corporate progress.
/PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and...
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing...
/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of...
Highlights from the Data Presentation Initial safety data presented on the first 10 chronically HBV-infected patients representing 674 patient days of...
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
/PRNewswire/ -- Cellenkos, Inc., a privately held, clinical stage biotech company that focuses on developing transformative T regulatory cell therapies for...
HOUSTON, Jan. 8, 2019 /PRNewswire/ -- Cellenkos® (Cellenkos), an early stage clinical biotechnology company developing umbilical cord blood-derived...
Generally, FDA-approved clinical trials progress through three phases: the first shows safety, the second starts to explore effects and the third seeks to
❮
❯